Therapeutic dendritic-cell vaccine for simian aids

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 27-32

  Lu, Wei ^a,b   Wu, Xiaoxian ^c   Lu, Yaozeng ^c   Guo, Weizhong ^c   Andrieu, Jean Marie ^a,b  

^a Inst de Recherche sur les Vaccins   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Tropical Medicine Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INACTIVATED WHOLE VIRUS PULSED DENDRITIC CELL VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; INFECTION CONTROL; INGUINAL LYMPH NODE; LYMPHOCYTE COUNT; MALE; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

2,2'-DIPYRIDYL; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISULFIDES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; LYMPH NODES; MACACA MULATTA; MALE; NEUTRALIZATION TESTS; OXIDANTS; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL LOAD;

ANIMALIA; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0037234103     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm806     Document Type: Article

References (37)

1. Kostense, S. et al. Persistent numbers of tetramer(+) CD8(+) T cells, but loss of interferon-γ(+) HIV-specific T cells during progression to AIDS. Blood 99, 2505-2511 (2002).
2. Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
3. Lieberman, J., Shankar, P., Manjunath, N. & Andersson, J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98, 1667-1677 (2001).
4. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
5. Cohen, O.J., Kinter, A. & Fauci, A.S. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159, 31-48 (1997).
6. Fenyo, E.M. & Putkonen, P. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Immunol. Lett. 51, 95-99 (1996).
7. Knight, S.C. & Stagg, A.J. Antigen-presenting cell types. Curr. Opin. Immunol. 5, 374-382 (1993).
8. Rossio, J.L. et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72, 7992-8001 (1998).
9. Buseyne, F. et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nature Med. 7, 344-349 (2001).
10. Mehlhop, E. et al. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J. Immunol. Methods 260, 219-234 (2002).
11. Sapp, M. et al. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol. Lett. 66, 121-128 (1999).
12. Chougnet, C. et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J. Immunol. 163, 1666-1673 (1999).
13. Lu, W., Achour, A., Arlie, M., Cao, L. & Andrieu, J.M. Enhanced dendritic-cells-driven proliferation and anti-HIV activity of CD8+ T cells by a new phenothiazine derivative aminoperazine. J. Immunol. 167, 2929-2935 (2001).
14. Lu, W. & Andrieu, J.M. In vitro HIV eradication by autologous CD8+ T cells expanded with inactivated-virus-pulsed dendritic cells. J. Virol. 75, 8949-8956 (2001).
15. Hirsch, V.M. & Lifson, J.D. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv. Pharmacol. 49, 437-477 (2000).
16. Lu, W., Cao, L., Ty, L., Arlie, M. & Andrieu, J.M. Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: applications for universal detection and quantitation. Nature Med. 5, 1081-1085 (1999).
17. Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369 (1998).
18. Salerno-Goncalves, R., Lu, W. & Andrieu, J.M. Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease. J. Virol. 74, 6648-6651 (2000).
19. Lu, W. & Andrieu, J.M. Prospective views of HIV pathology. Clues for therapeutic strategies. Adv. Exp. Med. Biol. 374, 235-242 (1995).
20. Andrieu, J.M. & Lu, W. Viro-immunopathogenesis of HIV disease: implications for therapy. Immunol. Today 16, 5-7 (1995).
21. Hermans, I.F., Ritchie, D.S., Yang, J., Roberts, J.M. & Ronchese, F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164, 3095-3101 (2000).
22. Norbury, C.C., Malide, D., Gibbs, J.S., Bennink, J.R. & Yewdell, J.W. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nature Immunol. 3, 265-271 (2002).
23. McIlroy, D. et al. Low CD83, but normal MHC class II and costimulatory molecule expression, on spleen dendritic cells from HIV+ patients. AIDS Res. Hum. Retroviruses 14, 505-513 (1998).
24. Zimmer, M.I. et al. Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood 99, 2859-2868 (2002).
25. Ludewig, B. et al. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol. 163, 1839-1844 (1999).
26. Jin, X. et al. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol. Med. 6, 803-809 (2000).
27. Kalams, S.A. et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73, 6721-6728 (1999).
28. Gray, C.M. et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162, 1780-1788 (1999).
29. Pacanowski, J. et al. Reduced blood CD123+ (lymphoid) and CD11 c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98, 3016-3021 (2001).
30. Feldman, S. et al. Decreased interferon-α production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin. Immunol. 101, 201-210 (2001).
31. Donaghy, H. et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98, 2574-2576 (2001).
32. Grassi, F. et al. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. Aids 13, 759-766 (1999).
33. Grabar, S. et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133, 401-410 (2000).
34. Lederman, M.M. & Valdez, H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 284, 223-228 (2000).
35. Hatano, H. et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. Aids 14, 1357-1363 (2000).
36. Davey, R.T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109-15114 (1999).
37. Lu, W. & Andrieu, J.M. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 96, 250-258 (2000).